Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
One-Liner
A tool connecting Indian pharmaceutical bioequivalence study expertise to Japanese generic drug substitution regulatory compliance requirements.
AI Thinking Process
Japan's generic substitution reform (2023-2025) targets 80% generic penetration by 2029. Indian pharma has globally competitive bioequivalence workforce. Cross-domain signal: can Indian BE study execution capacity be matched with Japanese generic manufacturers needing faster, cheaper PMDA submissions?
Structural Pastor detected: Japanese generic manufacturers' regulatory affairs departments are identity-locked to in-house BE study execution. PMDA reviewer posture toward Indian data is shaped by Ranbaxy 2013 cGMP enforcement action — a precedent that persists in institutional memory. CRO incumbents Quotient, PRA, Eurofins already have Japan desks absorbing this workflow.
KILLED: structural adoption barrier. Japanese authorized generic pivot — buyer pool too small. Korean generics pivot — no software wedge, reduces to a staffing/salesforce model. Adoption barrier is structural, not solvable by better product design.
Kill Reason
Structural barrier at the regulatory-affairs department — Japanese generic manufacturers' RA departments have identity tied to running bioequivalence studies in-house, plus the Ranbaxy 2013 cGMP scandal echoes shape PMDA reviewer behavior toward Indian data. CRO incumbents (Quotient, PRA, Eurofins) absorb via Japan desks.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Novotech CRO — the dominant APAC CRO — already has an India hub, Australia desk, rare-disease vertical, and a stated productized patient recruitment offering. Pass 1 named global CROs (Parexel, ICON, Syneos) and missed the APAC-native incumbent. Additionally, the load-bearing CDSCO-TGA mutual-recognition MoU claim was unverified (single source only).
killed: Passive voice-based depression detection requires FDA Software as a Medical Device clearance for any diagnostic claim; a "wellness" framing undercuts the core value proposition and reduces willingness to pay. Epic Systems and large telehealth platforms are already integrating validated mental health screening tools into clinical workflows, crowding out standalone apps before they achieve scale.
killed: Google Nest Hub's built-in Soli radar-based sleep sensing already delivers contactless respiratory monitoring in millions of households, and Withings has shipped FDA-cleared sleep apnea screening hardware. A standalone $30 WiFi module cannot match the distribution, brand trust, or regulatory standing of these well-resourced incumbents.